Chalfont St. Giles, UK - GE Healthcare, a unit of General Electric Company, today announced it has acquired Wave Biotech LLC, a supplier of innovative disposable manufacturing technologies for the biopharmaceutical industry. The acquisition of Wave Biotech LLC including its subsidiary Wave Europe Pvt. Ltd. will allow GE Healthcare to expand its offering of products and services for the manufacture of biopharmaceuticals such as antibodies and vaccines. Financial terms were not disclosed.
Wave Biotech develops and manufactures unique bioreactors which are designed to replace traditional and more expensive stainless steel tanks and piping. The patented products offer considerable advantages such as more rapid installation, potentially reducing time to market, and significantly lower costs by eliminating the need for cleaning and validating between batches. The equipment is already in use in over three hundred companies worldwide. Wave Biotech single use bioreactors are also increasingly being used to enable the manufacture of patient-specific cell and gene therapy products.
Ann O’Hara, General Manager of GE Healthcare’s BioProcess business, said “Wave Biotech is an excellent company with a strong track record of innovation and a product range that is highly complementary with our existing BioProcess business. The combination of GE Healthcare and Wave Biotech will allow us to expand into new applications and to create a broad offering of added value tools and services for biopharmaceutical manufacture.”
"We are very excited to be part of GE Healthcare, who already offer a broad range of technologies and services to the biopharmaceutical manufacturing industry” said Dr. Vijay Singh, President and founder of Wave Biotech. "Our customers will benefit greatly from the global presence and the R&D resources that GE Healthcare brings to the table. The integration of single-use cell culture with GE Healthcare’s existing filtration and downstream operations will provide a host of new disposable solutions to this growing industry."
SOURCE: GE Healthcare Life Sciences